In line with this suggestion, serum chemerin was not changed in non-alcoholic fatty liver disease (NAFLD) patients with increasing steatosis, inflammation and fibrosis grades [44]. Here, RARRES2 is linked to metabolic dysfunction-associated steatotic liver disease.